Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for CDK6 protein
Most Correlated Studies
- HeLa cells after G0-G1 / G1-S arrest release with CDK4/6 shRNA and IL-1a treated
- Breast cancer MCF-7 cells with Abemaciclib and SR11302
- Granulocyte-monocyte progenitors treated with cyclosporine A (CsA) or FK506
- Acute myeloid leukemia MV4-11 cells treated with BSJ-03-123, YKL-06-102 and palbociclib
- Breast cancer MCF7 cells ER+ with acquired fulvestrant resistance
Most Relevant Literature
- Stabilization of CDK6 by ribosomal protein uS7, a target protein of the natural product fucoxanthino…
- Targeting CDK6 in hormone receptor-positive breast cancer: inhibitor discovery for precision oncolog…
- Unveiling Conformational States of CDK6 Caused by Binding of Vcyclin Protein and Inhibitor by Combin…
- CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver.
- CDK6 protein expression is associated with disease progression and treatment resistance in multiple …
Most Relevant Clinical Trials
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Enc…
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amp…
- Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Pati…
- Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Ampli…
